all trans retinoic acid

Phase 3Small molecule

Mario Negri Institute for Pharmacological Research

all trans retinoic acid is one of 227 small molecule programs targeting Glioma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

226

Competitors

Pipeline

Status by Indication[3][1]

Indication

GliomaRecruiting

LeiomyosarcomaRecruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Acute Myeloid LeukemiaCompleted

Acute Promyelocytic LeukemiaRecruiting

Solid CancerRecruiting

Maintenance TherapyNot yet recruiting

GliomaPhase 2

Recruiting

LeiomyosarcomaPhase 2

Recruiting

Colorectal CancerPhase 2

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Acute Myeloid LeukemiaPhase 3

Completed

Acute Promyelocytic LeukemiaPhase 2

Recruiting

Solid CancerPhase 2

Recruiting

Maintenance TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

all trans retinoic acid

Mario Negri Institute for Pharmacological Research

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 6

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

Active Comparator

Moderna

Preclinical

1 10

Cyclophosphamid

EEssen Biotech

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Solid Cancer

NCT06439888

Q3 2027

N/AActive, not recruiting

Acute Promyelocytic Leukemia

NCT07187505

Q4 2027

Phase 2Recruiting

Acute Promyelocytic Leukemia

NCT04793919

Phase 2Not yet recruiting

Maintenance Therapy

NCT06646666

Phase 2Recruiting

Leiomyosarcoma

NCT06528769

Q2 2028

Phase 2Recruiting

Glioma

NCT05345002

Clinical

Trials by Indication[1]

Acute Myeloid Leukemia4 trials

Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·UUniversity of Ulm·Phase 2/3·NCT00151242·920 enrolled

Efficacy and Safety of ATO Plus ATRA in Nucleophosmin-1 Mutated Acute Myeloid Leukemia

Enrolling by invitation·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 1/2·NCT03031249·80 enrolled

All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Completed·UUniversity of Ulm·Phase 3·NCT00151255·500 enrolled

Show 1 more trial

Treatment of Acute Myeloid Leukemia With Arsenic and All-trans Retinoid Acid

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 1·NCT05297123·30 enrolled

Acute Promyelocytic Leukemia4 trials

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

Active, not recruiting·—·N/A·NCT07187505·28 enrolled

Treatment of Non-high-risk Acute Promyelocytic Leukemia (APL) With Realgar-Indigo Naturalis Formula (RIF)

Unknown status·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 3·NCT02899169·110 enrolled

Treatment Study for Children and Adolescents With Acute Promyelocytic Leukemia

Recruiting·AAssociazione Italiana Ematologia Oncologia Pediatrica·Phase 2·NCT04793919·89 enrolled

Show 1 more trial

Phase III Trial in Acute Promyelocytic Leukemia Patients

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto·Phase 3·NCT00482833·276 enrolled

Treatment3 trials

A Study of ATRA in the Treatment of ITP

Unknown status·PPeking University People's Hospital·Phase 2·NCT04618328·80 enrolled

Study of Sensitization of Non-M3 AML Blasts to ATRA by Epigenetic Treatment With Tranylcypromine (TCP)

Unknown status·MMichael Luebbert·Phase 1/2·NCT02717884·60 enrolled

The Combination of ATRA and Eltrombopag as the Treatment of Steroid-resistant/Relapse ITP Based on MSC-C5b-9

Completed·PPeking University People's Hospital·Phase 3·NCT05438875·96 enrolled

Breast Cancer2 trials

Investigating the Potential Role of a Novel Quadrate Combination Therapy Mifepristone(Antiprogestrone), Tamoxifen, Retinoic Acid and Cannabidiol ( Selective Cyp 26 Inhibitor) for Treating Early Breast Cancer.

Unknown status·MMahmoud Ramadan mohamed Elkazzaz·Phase 3·NCT05016349·160 enrolled

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

Terminated· Mario Negri Institute for Pharmacological Research logo

Mario Negri Institute for Pharmacological Research·Phase 2·NCT04113863·76 enrolled

Immune Thrombocytopenia2 trials

The Combination of Low-dose Rituximab and ATRA as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Unknown status·PPeking University People's Hospital·Phase 2·NCT03304288·168 enrolled

The Combination of ATRA and Danazol as Second-line Treatment in Adult Immune Thrombocytopenia

Completed·PPeking University People's Hospital·Phase 2·NCT01667263·130 enrolled

15 more indications

Myelodysplastic Syndrome2 trials

Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

Completed·UUniversity of Pittsburgh·Phase 1·NCT00892190·9 enrolled

A Study of All-Trans Retinoic Acid (ATRA) and Bryostatin in Patients With Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)

Completed·—·Phase 2·NCT00136461·40 enrolled

Effectiveness1 trial

Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL

Unknown status·HHospital Universitario Dr. Jose E. Gonzalez·Phase 1/2·NCT05497310·15 enrolled

Glioma1 trial

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Recruiting·SStephen Bagley, MD, MSCE·Phase 2·NCT05345002·55 enrolled

Prostate Cancer1 trial

A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment

Completed·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT03572387·14 enrolled

Maintenance Therapy1 trial

ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCT

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06646666·35 enrolled

Leiomyosarcoma1 trial

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Recruiting·GGabriel Tinoco·Phase 2·NCT06528769·16 enrolled

Colorectal Cancer1 trial

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Active, not recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT05999812·22 enrolled

Pancreatic Cancer1 trial

Nivolumab and All-trans Retinoic Acid for Pancreatic Cancer

Active, not recruiting·—·Phase 1·NCT05482451·10 enrolled

Sclerosing Cholangitis1 trial

An Efficacy Trial of Low Dose All-trans Retinoic Acid in Patients With Primary Sclerosing Cholangitis

Terminated·YYale University·Phase 2·NCT03359174·2 enrolled

Solid Cancer1 trial

Lymphocyte Support to SBRT in Patients With Oligo-metastatic Solid Cancer

Recruiting·GGustave Roussy, Cancer Campus, Grand Paris·Phase 1/2·NCT06439888·58 enrolled

Adenoid Cystic Carcinoma1 trial

All-trans Retinoic Acid (ATRA) in the Treatment of Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck

Unknown status·SShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University·Phase 2·NCT04433169·30 enrolled

Multiple Myeloma1 trial

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Terminated·HHackensack Meridian Health·Phase 2·NCT04700176·1 enrolled

Chemotherapy1 trial

Nivolumab With Chemotherapy in Refractory MDS

Terminated·SSt. Petersburg State Pavlov Medical University·Phase 1/2·NCT03259516·2 enrolled

Newly Diagnosed1 trial

Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05175508·180 enrolled

Emphysema1 trial

Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00000621

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for all trans retinoic acid. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — all trans retinoic acid compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for all trans retinoic acid. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mario Negri Institute for Pharmacological Research company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Mario Negri Institute for Pharmacological Research

all trans retinoic acid

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q4 2027

Q2 2028

Trials by Indication[1]

Acute Myeloid Leukemia4 trials

Acute Promyelocytic Leukemia4 trials

Treatment3 trials

Breast Cancer2 trials

Immune Thrombocytopenia2 trials

Myelodysplastic Syndrome2 trials

Effectiveness1 trial

Glioma1 trial

Prostate Cancer1 trial

Maintenance Therapy1 trial

Leiomyosarcoma1 trial

Colorectal Cancer1 trial

Pancreatic Cancer1 trial

Sclerosing Cholangitis1 trial

Solid Cancer1 trial

Adenoid Cystic Carcinoma1 trial

Multiple Myeloma1 trial

Chemotherapy1 trial

Newly Diagnosed1 trial

Emphysema1 trial

References

Drug Info

Quick Facts

Related News